Description: Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
Home Page: www.zelgen.com
No. 209, Chenfeng Road
Kunshan,
215300
China
Phone:
86 512 5701 8310
Officers
| Name | Title |
|---|---|
| Mr. Zelin Sheng | Chairman & GM |
| Mr. Gang Huang | CFO & Deputy GM |
| Ms. Zeqi Sheng | Chief Scientific Officer |
| Ms. Huiping Lu | Exec. Deputy GM & Director |
| Mr. Jisheng Wu | Director & Deputy GM |
| Mr. Binhua Lv | Deputy Gen. Mang. & Director |
| Ms. Qingping Gao | Deputy GM & Board Sec. |
Exchange: SHG
Country: CN
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.1238 |
| Price-to-Sales TTM: | 35.4273 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 688 |